Abstract
Prevalence of obesity and related complications such as type 2 diabetes (T2D) has increased dramatically in recent decades. Metabolic complications of obesity arise in part due to subcutaneous adipose tissue (SAT) dysfunction. However, it is currently unclear why some obese individuals develop insulin resistance and T2D and others do not. In this review, we discuss the role of the skin in regulating SAT function, and whether presence of inflammatory skin diseases such as psoriasis represent a novel risk mechanism mediating development of obesity-related complications.

Highlights
· Subcutaneous adipose tissue dysfunction is central for development of insulin resistance
· Psoriasis is an independent risk-factor for development of T2D
· Skin-specific transgenic mice display altered whole-body glucose and lipid homeostasis
· Subcutaneous adipose tissue function is impaired directly below psoriatic skin lesions
· The skin secretes proteins and peptides which can enhance or impair metabolic control
Can the Skin Make You Fat? A role for the skin in regulating adipose tissue function and whole-body glucose and lipid homeostasis.

Caton PW1, Evans E1, Philpott MP2 and Hannen RF2

1Division of Diabetes and Nutritional Sciences, King’s College London, London SE1 9UL, UK
2Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London E1 2AT

Correspondence to: Dr Paul W. Caton, Division of Diabetes and Nutritional Sciences, King’s College London, London SE1 1UL, UK, Tel: +44 2078486436, paul.w.caton@kcl.ac.uk, Short Title

Skin and metabolic health

Highlights

· Subcutaneous adipose tissue dysfunction is central for development of insulin resistance

· Psoriasis is an independent risk-factor for development of T2D

· Skin-specific transgenic mice display altered whole-body glucose and lipid homeostasis

· Subcutaneous adipose tissue function is impaired directly below psoriatic skin lesions

· The skin secretes proteins and peptides which can enhance or impair metabolic control

Abstract

Prevalence of obesity and related complications such as type 2 diabetes (T2D) has increased dramatically in recent decades. Metabolic complications of obesity arise in part due to subcutaneous adipose tissue (SAT) dysfunction. However, it is currently unclear why some obese individuals develop insulin resistance and T2D and others do not. In this review, we discuss the role of the skin in regulating SAT function, and whether presence of inflammatory skin diseases such as psoriasis represent a novel risk mechanism mediating development of obesity-related complications.

Obesity and Adipose tissue

Obesity and its associated metabolic complications, including type 2 diabetes (T2D) and cardiovascular disease, have increased dramatically in recent decades. Global prevalence of obesity and overweight were estimated at 2.1 billion individuals in 2014[1], whilst the number of people with T2D is predicted to rise from 382 million in 2013 to 592 million by 2035. This increased disease burden has become a major public health issue, with increased morbidity and mortality and associated socioeconomic costs [1], with costs of obesity and related complications estimated at $2 trillion globally. There is a widely-recognised association between obesity-related metabolic diseases and
skin disease[2]. For example, psoriasis is an independent risk factor for development of T2D. Here we discuss the contribution of the skin in driving adipose tissue dysfunction and onset of T2D.

White adipose tissue (AT) plays an essential role in metabolic homeostasis, via its role in storage and release of lipids and fatty acids, respectively; through its role as an endocrine organ, and as a location of beige adipogenesis. Conversely, dysfunction of white AT function is a central aspect of obesity related pathophysiology [1]. White AT is present as two major distinct depots; visceral AT (VAT) which is mainly located in intra-abdominal (mesenteric), pericardial and peri-renal regions, and subcutaneous adipose tissue (SAT) located in the hypodermic regions below the skin [1].

**SAT and metabolic homeostasis**

SAT is the largest adipose tissue depot and as a result plays a key role in regulating whole-body glucose and lipid homeostasis via its endocrine and lipid storage and release functions as well as a major site of beige adipocyte formation[3]. Consequently, dysregulation of SAT function is a central factor in the pathophysiology of obesity-induced insulin resistance and T2D [4, 5]. SAT is regarded as the primary adipose tissue depot for safe storage of lipids, in the form of triacylglycerols (TAG) [3]. However, the ability of SAT to expand in response to chronic over-nutrition is limited and when energy supply exceeds the capacity of SAT to store lipids, fat is instead stored in non-adipose tissue such as liver and skeletal muscle and also in VAT depots, a process referred to as ectopic lipid deposition [4]. Studies have demonstrated that the limited potential of SAT to expand is a key mediating factor in the dysfunction of SAT and the development of obesity associated insulin resistance and T2D[6]. Healthy adipogenesis occurs largely via adipocyte hyperplasia – i.e. the formation of new adipocytes from adipocyte precursor cells. In contrast, in obesity adipocyte hyperplasia can become impaired leading SAT expansion to occur primarily through adipocyte hypertrophy, i.e. expansion of existing adipocytes [7, 8]. This can lead directly to impaired SAT function, characterised by angiogenesis, hypoxia and adipocyte cell death. As a result, lipid storage capacity declines, immune cell infiltration and SAT inflammation develop and insulin sensitivity and adipocytokine secretion become impaired [7, 9, 10]. The importance of dysregulation of SAT expansion in obesity pathophysiology is emphasised by the fact that presence of hypertrophic adipocytes is a strong, early predictor of developing insulin resistance and T2D in first degree relatives of individuals with T2D, as well being a major phenotype in non-obese individuals with T2D[11, 12].
**SAT dysfunction and ectopic lipid deposition**

Loss of SAT storage capacity results in in ectopic lipid deposition in VAT, liver, skeletal muscle and pancreas [3, 7, 8, 13]. In liver and muscle, this can lead to build-up of toxic lipid metabolites such as diacylglycerols (DAG) and ceramides, which directly promote tissue insulin resistance. Specifically, DAGs induce serine phosphorylation of IRS1/2[14, 15], whilst ceramides promote dephosphorylation of AKT [16], resulting in decreased insulin signalling transduction. In the pancreas, excess lipid levels can impair insulin secretion and beta-cell proliferation [17, 18]. Deposition of excess lipid into VAT depots results in VAT expansion and consequent dysfunction. In addition, in all these tissues, saturated fatty acids released from SAT can directly induce inflammatory signalling pathways [18, 19]. These include induction of TLR4 signalling together with increased reactive oxygen species production, which can both directly inhibit insulin signalling.

Obesity also leads to impaired SAT endocrine function. SAT secretes bioactive proteins and peptides (adipocytokines) including adiponectin, retinol binding protein (RBP4), resistin and various pro-inflammatory cytokines and chemokines (MCP1, TNFα, IL6) [20-22]. In addition, SAT can also secrete insulin sensitising anti-inflammatory bioactive lipids, including palmitoleate[23] and the recently identified fatty-acid esters of hydroxyl fatty acids (FAHFAs)[24]. Dysfunction of SAT leads to altered expression and endocrine profile, broadly characterised by reductions in anti-inflammatory, insulin sensitisers (adiponectin, FAHFAs, palmitoleate) and increases in RBP4, resistin and pro-inflammatory cytokines which exert deleterious effects on whole-body insulin sensitivity [22, 25]. Interestingly, dysregulation of SAT endocrine function is related in part to adipocyte insulin sensitivity and levels and activity of insulin-dependent glucose transporter 4 (GLUT4) [3]. Despite AT glucose uptake only accounting for 10 – 15% of total insulin-stimulated glucose uptake, AT GLUT4 levels are an accurate marker of insulin sensitivity, whilst AT-GLUT4 KO mice display the same severity of insulin resistance as skeletal muscle GLUT4 KO mice [26]. This important role of AT-GLUT4 is due to its role in SAT endocrine function. Reduced levels of AT-GLUT4 lead to increased expression and secretion of RBP4 and reductions in ChREBP-mediated synthesis and secretion of FAHFAs [24, 27]. Together, the changes in endocrine function observed in obese dysfunctional SAT are directly related to development of obesity-mediated pathologies including insulin resistance and T2D.

A final mechanism linking SAT dysfunction and insulin resistance involves beige adipogenesis. SAT is the primary site for the formation of beige adipocytes, which are brown adipocyte cells located within classical white AT depots [28]. Beige adipocytes develop from a different lineage to classical brown
adipocytes, but retain many of the same functional characteristics, including induction by thermogenic triggers such as cold/noradrenaline and morphological characteristics, such as expression of uncoupling protein 1 (UCP1), presence of multilocular lipid droplets, numerous mitochondria and abundant vascularisation and innervation[28]. Moreover, induction of beige adipogenesis (‘browning’ of white adipose tissue) – via mechanisms including non-shivering thermogenesis and exercise [29, 30] - has been demonstrated to exert beneficial effects on insulin sensitivity and glucose tolerance. The fact that these browning effects are lost or reduced in obesity and diabetes further emphasises the importance of beige adipocytes in SAT mediated maintenance of whole-body glucose metabolism[30, 31].

Taken together, the local and systemic functions of SAT play a critical contributory role in the maintenance of whole-body glucose and lipid homeostasis. Conversely, SAT dysfunction plays a crucial role in the pathophysiology of obesity-mediated onset of insulin resistance and T2D. Consequently, elucidating the underlying mechanisms, and specifically the genetic and environmental factors, that lead to dysregulation of SAT is essential in order to fully understand the pathophysiology of T2D and to identify novel prevention and treatment approaches. The understanding of these mechanisms is of particular importance since many obese individuals do not develop insulin resistance – a condition referred to as metabolically healthy obesity – in large part due to insufficient adipocyte hyperplasia enabling excess energy storage. However, the genetic and environmental factors which cause inter-individual differences in response to obesity remain unclear [10, 32].

**A role for the skin in regulating SAT function and glycaemic control**

The importance of inter-organ cross-talk in the regulation of insulin sensitivity is widely recognised. In addition to the important roles for bioactive adipocytokines and lipokines secreted from adipose tissue, an endocrine function of skeletal muscle (myokines) and liver (hepatokines) is also reported [33-36]. A large number bioactive factors are secreted from these tissues with both beneficial and deleterious effects on glucose metabolism reported, with secretion profiles altered in obesity and diabetes. However, despite being the largest organ in the body with an established secretory function, a potential role for the skin in regulating insulin sensitivity and glucose homeostasis has not been examined.
Clinical, epidemiological and experimental evidence supporting a direct role for skin in glycaemic control.

In support of this idea, accumulating evidence suggests a role for the skin in regulating whole-body glucose metabolism. The association between psoriasis and obesity has long been recognised, with the earliest evidence based on a study on prisoners of war during world war II in which psoriasis improved with caloric restriction [2, 37]. Since then, a number of studies have shown a direct link between psoriasis and obesity, and that each condition can drive the other. Clinical and epidemiological studies have demonstrated that the inflammatory skin disease psoriasis is an independent risk factor for development of T2D, as well as related metabolic conditions such as NAFLD and CVD [38-42]. For example, a systematic review and meta-analysis concluded that a nearly 30% increased risk of developing T2D was associated with psoriasis [43]. More recently, a population based study showed that patients with comorbid psoriasis who were diagnosed with T2DM were significantly younger at the age of diagnosis than non-psoriasis patients [44], whilst T2D patients with psoriasis present with increased disease severity compared to T2D patients without psoriasis [44]. Moreover, severity of psoriasis has been shown to correlate with both increased likelihood of developing T2DM and with increased rate of progression to requirement for exogenous insulin [38]. Similar associations have been reported between psoriasis and both non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) [41, 42]. Experimental studies also support a specific role for skin in regulating whole-body glucose and lipid homeostasis. Mice with a keratinocyte-specific knockout of SCD1, a key lipogenic gene, showed altered whole-body glucose and lipid metabolism, including altered lipogenic gene expression in liver and skeletal muscle, and altered glucose tolerance and hepatic glycogen content [45]. This implies that specific signalling pathways within the skin can exert systemic effects to regulate whole-body glucose and lipid homeostasis, and have the potential to play an important role in development of T2D.

Thus, associations between skin inflammation, insulin resistance and T2D are well established. Research to date has largely focussed on obesity itself, via altered adipocytokine secretion from dysfunctional adipose tissue, as the primary risk factor linking psoriasis with T2D. However, as detailed above, many studies have demonstrated that psoriasis and skin health are independent risk factors and that associations between psoriasis and T2D are independent of underlying obesity [46]. This suggests that impaired skin function itself may be an underlying contributory factor in the development of T2D. In addition, other recognised causes of increased T2D risk, such as ageing and
exposure to atmospheric pollution [47, 48], are also characterised by declining skin health and presence of skin inflammation [49, 50].

**Mechanisms linking skin health to whole-body metabolism: the skin secretome and SAT?**

The underlying mechanisms linking skin function to whole-body metabolism are unclear but potentially relate to skin endocrine function. Analysis using LCMS/MS as well as candidate protein approaches have begun to characterise the skin secretome. Sebocytes, the secretory cells of the sebaceous gland, have been reported to secrete adipokines including IL6, leptin and eNAMPT/visfatin, as well as serpin E1 [51]. Of relevance to skin inflammation, expression and secretion of these proteins was upregulated following TLR2/4 activation. Separately, LCMS/MS analysis has shown sebocytes to secrete lipocalin 2 (LCN2) and complement C3 [52]. Keratinocytes are reported to secrete small molecules and proteins including glucocorticoids, mineralocorticoids, serpins B1 and E1, anti-microbial peptides (e.g. LL37), eNAMPT/visfatin, IL6 and apolipoprotein E [35, 51, 53-56]. In addition, a wide range of pro-inflammatory cytokines and chemokines, including TNF-α, IL6, IL8, IL17, and IL1-β, are also secreted from both keratinocytes and immune cells within the skin [39, 40, 55, 57, 58]. Importantly, such cytokines as well as many of the skin-derived proteins described above, have been separately shown to exert well described gluco- and lipo-regulatory effects on metabolic target tissues [35, 46, 59-63]. This, together with the fact that skin expression and secretion of a number of these bioactive mediators are altered in psoriasis and ageing [64-66], provides a plausible link between skin inflammation, poor skin function and development of insulin resistance and T2D. Given that SAT is anatomically adjacent to skin, it is rationale to hypothesise that SAT would be a primary recipient of signalling factors derived from inflamed skin. Exposure of SAT to e.g. inflammatory stimuli is has been shown to impair glucose uptake, lipid storage, adiponectin secretion, promote SAT inflammation and reduce beige adipogenesis. Thus, skin inflammation may directly induce SAT dysfunction with consequent increased risk of development of insulin resistance and T2D. In support of this, a recent study demonstrated that in psoriasis, expression of specific miRNAs are upregulated in SAT located directly below psoriatic skin, leading to impaired regulation of cholesterol efflux [67]. Specifically, miR-26b-5p was upregulated, and found to down regulate the essential cholesterol efflux enzyme neutral cholesterol ester hydrolase 1 various SAT cells including adipocytes, monocytes/macrophages, and vascular endothelial cells. A separate study has also reported increased SAT inflammation in psoriasis patients [68]. Whilst these studies do not directly establish directionality, such altered cholesterol regulation and inflammation provide plausible links between psoriasis and related co-morbidities via direct impairment of SAT function. Separately from
inflammatory effects, some rodent studies have pointed to a potential role for skin in regulating browning of SAT. Defects in the barrier and thermoregulatory functions of skin, as are observed in psoriasis, are noted to lead to cold-induced beige adipogenesis, whilst other mouse studies have indirectly linked skin function with SAT browning [69].

In summary, alterations in the skin secretome linked to inflammatory skin disease and declining skin health may play an important role in mediating SAT dysfunction, resulting in increased predisposition to obesity-associated development of insulin resistance and T2D. Moreover, presence of inflammatory skin disease or poor skin health may partly explain inter-individual differences in SAT responses to over-nutrition and provide insight into the underlying mechanisms of metabolically healthy obesity. We hypothesise that maintaining skin health or treating inflammatory skin disease may represent a novel approach for prevention or treatment of obesity-related metabolic complications.

Funding: This work was supported by the following funding: BBSRC-LIDO Studentship (PWC, MPP and EE); Diabetes UK project grant (15/0005154) (PWC); British Skin Foundation (RFH, MP); MedCity (RFH)

References

** Excellent overview of the importance of subcutaneous adipose tissue in metabolic homeostasis **


**The authors show that psoriasis is an independent risk-factor for T2D development**


**This study shows that T2D clinical symptoms are worse in patients with psoriasis than those without psoriasis**


**Proof-of-concept study showing that alterations in skin-specific pathways can impact wholebody glucose and lipid metabolism**


**Interesting study showing that sebocytes within the skin secrete adipokines**


**The authors describe the importance of skin-derived glucocorticoids in psoriasis. Changes in secretion of steroids from skin may play a key role in regulating local SAT function**

Cho KA, Suh JW, Lee KH, Kang JL, Woo SY (2012) IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1beta by keratinocytes via the ROS-NLRP3-caspase-1 pathway. International immunology 24: 147-158


**A proteomic analysis of the skin secretome in psoriatic skin**


The authors describe changes in SAT function directly below psoriatic lesions, providing the first evidence that secretions from psoriatic skin may influence underlying adipose tissue function


A  
Healthy skin

Epidermis

Dermis

White adipocytes

Beige adipocytes

Glucose
Adiponectin
Anti-inflammatory lipids

Tissue and systemic insulin sensitivity and decreased T2D risk

B  
Inflamed skin

Epidermis

Inflammation

Dermis

Inflammatory skin-derived factors

Macrophage infiltration

Hypertrophic adipocytes

Glucose
NEFA
RBP4
TNFα

Tissue and systemic insulin resistance and increased T2D risk
Figure 1: Diagram demonstrating how skin inflammation may impair whole-body glucose homeostasis via SAT dysfunction. (A) Healthy skin displays limited inflammation and does not secrete pro-inflammatory cytokines or other deleterious skin-derived factors. Underlying SAT is healthy, characterised by small hyperplastic adipocytes, beige adipogenesis, insulin sensitivity and glucose uptake, adequate lipid storage capacity and secretion of insulin sensitising and anti-inflammatory proteins and lipids. (B) Skin is inflamed and the epidermis and dermis are infiltrated by immune cells, resulting in secretion of proinflammatory cytokines, anti-microbial peptides and other components of the skin secretome. Exposure to skin-derived inflammatory proteins leads to dysfunction of underlying SAT, characterised by large hypertrophic adipocytes, impaired insulin sensitivity and glucose uptake, inadequate lipid storage capacity, macrophage infiltration, secretion of inflammatory proteins and fatty acids, ultimately leading to development of systemic insulin resistance and risk of T2D. NEFA – non-esterified fatty acids; RBP4 – retinol binding protein 4; TNFa – tumour necrosis factor alpha
Conflicts of interest: none